rs879254603
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PM1PM2PM5PP3_StrongPP5
The NM_000527.5(LDLR):c.632A>T(p.His211Leu) variant causes a missense change. The variant allele was found at a frequency of 0.00000137 in 1,461,382 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. H211Y) has been classified as Pathogenic.
Frequency
Consequence
NM_000527.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LDLR | NM_000527.5 | c.632A>T | p.His211Leu | missense_variant | 4/18 | ENST00000558518.6 | NP_000518.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LDLR | ENST00000558518.6 | c.632A>T | p.His211Leu | missense_variant | 4/18 | 1 | NM_000527.5 | ENSP00000454071.1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1461382Hom.: 0 Cov.: 33 AF XY: 0.00000275 AC XY: 2AN XY: 726972
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Hypercholesterolemia, familial, 1 Pathogenic:3
Likely pathogenic, criteria provided, single submitter | literature only | LDLR-LOVD, British Heart Foundation | Mar 25, 2016 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Human Genome Sequencing Center Clinical Lab, Baylor College of Medicine | Jan 14, 2020 | The c.632A>T variant in the LDLR gene results in an amino acid change from a histidine to a leucine at codon 211 of encoded protein (p.His211Leu). Also known as p.His190Leu, this variant has been reported in a patient with familial hypercholesterolemia (PMID: 17347910). It is not present in the general population (gnomAD). Other missense variants affecting the same codon (p.His211Asp, p.His211Tyr) have been observed in unrelated individuals with familial hypercholesterolemia (PMID: 17765246, 23064986), suggesting the histidine residue is important for LDLR protein function. Multiple lines of in silico algorithms predict this p.His211Leu variant to be deleterious. Therefore, the c.632A>T (p.His211Leu) variant in the LDLR gene is classified as likely pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | May 30, 2024 | This missense variant replaces histidine with leucine at codon 211 of the LDLR protein. This variant is also known as p.His190Leu in the mature protein. This variant alters a conserved histidine residue in the LDLR type A repeat 4 of the LDLR protein (aa 146-186), where pathogenic missense variants are found enriched (ClinVar-LDLR). Computational prediction tools indicate that this variant has a deleterious impact on protein structure and function. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in two individuals affected with familial hypercholesterolemia (PMID: 17347910; ClinVar SCV001539711.3) and in one individual affected with dyslipidemia (PMID: 34363016). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Different variants affecting the same codon, p.His211Tyr and p.His211Asp, are considered to be disease-causing (ClinVar variation ID: 251335, 251334), suggesting that histidine at this position is important for LDLR protein function. Based on the available evidence, this variant is classified as Likely Pathogenic. - |
Familial hypercholesterolemia Pathogenic:2Uncertain:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Human Genome Sequencing Center Clinical Lab, Baylor College of Medicine | Oct 01, 2021 | Automatically set to LPath based on study of VUS-LP variants - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 28, 2023 | This sequence change replaces histidine, which is basic and polar, with leucine, which is neutral and non-polar, at codon 211 of the LDLR protein (p.His211Leu). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with clinical features of familial hypercholesterolemia (PMID: 17347910; Invitae). This variant is also known as p.His190Leu. ClinVar contains an entry for this variant (Variation ID: 251337). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt LDLR protein function with a positive predictive value of 95%. This variant disrupts the p.His211 amino acid residue in LDLR. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 10570905, 21511053; Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Oct 22, 2020 | - - |
not provided Pathogenic:1Uncertain:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Nov 03, 2021 | PP3, PM2_supporting, PM5, PS4_moderate - |
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 22, 2017 | Variant summary: The LDLR c.632A>T (p.His211Leu) variant involves the alteration of a conserved nucleotide, resulting in a missense change in one of the low-density lipoprotein (LDL) receptor class A repeats (InterPro). 3/4 in silico tools predict a damaging outcome for this variant (SNPsandGO not captured due to non-functioning tool). This variant is absent from the large control database ExAC (0/120210 control chromosomes). The variant has been reported in one hypercholesterolemia patient without strong evidence for pathogenicity (Widhalm_JIMD_2007). Variants affecting the same codon, p.H211Y and p.H211D (also known as p.H190Y and p.H190D, respectively) have been reported in hypercholesterolemia patients, suggesting this residue is a mutation hotspot. LDLR crystal structure study suggested functional importance of codon H211(Rudenko_2002). Taken together, due to lack of clinical and functional data, this variant is currently classified as a VUS until more evidence becomes available. - |
Cardiovascular phenotype Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 27, 2023 | The p.H211L variant (also known as c.632A>T), located in coding exon 4 of the LDLR gene, results from an A to T substitution at nucleotide position 632. The histidine at codon 211 is replaced by leucine, an amino acid with similar properties. This alteration has been reported in subjects with familial hypercholesterolemia (FH) (Widhalm K et al. J Inherit Metab Dis, 2007 Apr;30:239-47; Ambry internal data). Another alteration at the same codon, p.H211Y (c.631C>T), has also been described in association with FH (Hopkins PN et al. J. Hum. Genet., 1999;44:364-7). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at